Probable cutaneous sarcoidosis associated with combined interferon-alpha and rebavirin therapy for chronic hepatitis C [1];Probable sarcoidose cutanee apres bi-therapie associant ribavirine et interferon-alpha pour une hepatite chronique virale C

Gastroenterologie Clinique et Biologique

Volumn 24, Issue 6-7, 2000, Pages 679-680

  Savoye, Guillaume ^a   Goria, Odile ^a   Herve, Sophie ^a   Riachi, Ghassan ^a   Noblesse, Isabelle ^a   Bastien, Laurent ^a   Courville, Philippe ^a   Lerebours, Eric ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LETTER; SARCOIDOSIS; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; MIDDLE AGED; SKIN DISEASE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; RIBAVIRIN; SARCOIDOSIS; SKIN DISEASES;

EID: 0034198788     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Effets secondaires de l'interferon-alpha
2. Sarcoidosis associated with interferon-α therapy for chronic hepatitis C
3. Sarcoid hypodermic nodules during viral hepatitis C treated with interferon-alpha and beta
4. Cutaneous sarcoid foreign body granulomas developping in sites of previous skin injury after systemic interferon-alpha treatment for chronic hepatitis C
5. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the precoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response